What Is Semaglutide?

Semaglutide is a peptide-based molecule in the GLP-1 receptor agonist class. GLP-1, or glucagon-like peptide-1, is a hormone the gut releases after eating. It signals the pancreas to secrete insulin in a glucose-dependent way, tells the liver to slow glucagon release, and acts on brain regions that regulate appetite and satiety. Semaglutide mimics that hormone but is engineered to resist the enzyme DPP-4, which normally breaks natural GLP-1 down within minutes.

The structural modification that gives semaglutide its long half-life is an albumin-binding fatty acid chain attached to the peptide backbone. That chain lets the molecule bind to circulating albumin proteins, which slows kidney clearance and extends the half-life to roughly one week in humans. That pharmacokinetic profile is what makes once-weekly dosing possible in the approved drugs.

Semaglutide exists in two delivery forms studied in trials: subcutaneous injection and oral tablet. The oral version uses an absorption enhancer called SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) to protect the peptide from stomach acid and improve uptake across the gastric mucosa. Both forms have been studied in large-scale human trials, which is unusual for a peptide compound.

Regulatory Status: Approved Drugs vs. Research Chemicals

Several branded drugs built on semaglutide have received FDA approval for specific indications. Ozempic (subcutaneous semaglutide, Novo Nordisk) was approved in December 2017 for glycemic control in adults with type 2 diabetes and, later, to reduce cardiovascular risk in that population. Wegovy (higher-dose subcutaneous semaglutide) was approved in June 2021 specifically for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Rybelsus (oral semaglutide) was approved in September 2019 for type 2 diabetes in adults.

These approvals apply to those specific branded products manufactured under FDA oversight. Raw semaglutide peptide sold by research chemical suppliers is not FDA-approved, has not gone through the same manufacturing quality controls, and carries no approved indication. The distinction matters because the safety and efficacy data from clinical trials were generated using the pharmaceutical-grade branded drugs, not compounded or research-grade material.

Compounded semaglutide became a separate regulatory issue during a period when Ozempic and Wegovy appeared on the FDA's drug shortage list. The FDA has issued guidance on this topic, and the situation has evolved over time. Readers interested in the current compounding status should check the FDA's official shortage and compounding pages directly, as the regulatory picture has changed and continues to change.

What Does the Human Trial Evidence Show?

Semaglutide has one of the largest randomized controlled trial (RCT) records of any peptide-based compound. The SUSTAIN trial program, a series of phase 3 RCTs published between 2016 and 2019, tested subcutaneous semaglutide against placebo and active comparators in adults with type 2 diabetes. SUSTAIN-6, published in the New England Journal of Medicine in 2016 with 3,297 participants, found that semaglutide reduced the rate of major adverse cardiovascular events (MACE) by 26 percent compared to placebo over 104 weeks.

For weight outcomes, the STEP trial program is the key evidence base. STEP 1, published in the New England Journal of Medicine in 2021, enrolled 1,961 adults with obesity but without diabetes. Participants receiving 2.4 mg subcutaneous semaglutide weekly lost an average of 14.9 percent of body weight over 68 weeks, compared to 2.4 percent in the placebo group. STEP 2 (2021, 1,210 participants with type 2 diabetes) showed a mean weight loss of 9.6 percent with the same dose. These are among the largest weight-loss effects documented in a pharmaceutical RCT outside of bariatric surgery comparisons.

The SELECT trial, published in the New England Journal of Medicine in 2023, enrolled 17,604 adults with overweight or obesity and established cardiovascular disease but without diabetes. Participants receiving semaglutide 2.4 mg weekly had a 20 percent lower rate of MACE over a mean follow-up of 39.8 months compared to placebo. This was the first large trial to show a cardiovascular benefit from a weight-management drug in a population without diabetes, and it formed part of the basis for an expanded FDA indication for Wegovy.

The PIONEER trial program examined oral semaglutide across eight phase 3 trials. PIONEER 6, published in the New England Journal of Medicine in 2019 with 3,183 participants, was a cardiovascular outcomes trial that showed non-inferiority to placebo on MACE, though it was not powered to show superiority. Across the PIONEER program, oral semaglutide consistently reduced HbA1c and body weight, though the absolute weight reductions were somewhat smaller than those seen with the injectable form.

What Are the Documented Side Effects and Safety Signals?

Across the SUSTAIN, STEP, and PIONEER trials, gastrointestinal effects were the most commonly reported adverse events. Nausea, vomiting, diarrhea, and constipation occurred more often in semaglutide groups than placebo groups. In STEP 1, nausea was reported by 44 percent of participants in the semaglutide group versus 16 percent in the placebo group. Most GI events were rated mild to moderate and tended to decrease over time, but they were the leading reason for discontinuation in several trials.

Thyroid C-cell tumors appeared in rodent studies at clinically relevant exposures. The mechanism involves GLP-1 receptors expressed on rodent thyroid C-cells. Human thyroid C-cells express these receptors at much lower levels, and no causal link to human thyroid cancer has been established in trial data. However, the FDA label for the approved drugs carries a boxed warning about this signal, and the drugs are contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Pancreatitis was observed at low rates in trials and is listed as a warning in the prescribing information. Gallbladder disease, including cholelithiasis and cholecystitis, occurred at higher rates in semaglutide groups in several trials, likely related to rapid weight loss affecting bile composition. Post-marketing surveillance has also raised questions about rare risks including gastroparesis and, more recently, non-arteritic anterior ischemic optic neuropathy, though causality in the latter has not been established. These signals are under ongoing study.

What Are Researchers Studying Beyond Approved Indications?

Several active clinical trials are examining semaglutide in contexts beyond its current approvals. Researchers are studying its effects in non-alcoholic steatohepatitis (NASH), now more commonly called metabolic dysfunction-associated steatohepatitis (MASH). A phase 2 trial published in the New England Journal of Medicine in 2021 with 320 participants found that subcutaneous semaglutide 0.4 mg daily for 72 weeks did not significantly improve liver fibrosis compared to placebo, though it did reduce liver inflammation and steatosis markers. Phase 3 trials in this area are ongoing.

Researchers are also investigating semaglutide's potential effects on kidney disease progression. The FLOW trial, a phase 3 RCT, enrolled adults with type 2 diabetes and chronic kidney disease. Results published in the New England Journal of Medicine in 2024 showed that semaglutide 1.0 mg weekly reduced the risk of a composite kidney outcome by 24 percent compared to placebo over a median follow-up of about 3.4 years. This was the first GLP-1 receptor agonist trial to show a dedicated kidney protection signal.

Addiction medicine researchers have noted that GLP-1 receptors are expressed in brain reward circuits, and animal studies have shown reduced alcohol and drug-seeking behavior with GLP-1 receptor agonists. Early human observational data and small trials have explored whether semaglutide affects alcohol use disorder and other substance use patterns. These investigations are at an early stage, and no conclusions about efficacy in addiction contexts can be drawn from the current evidence. Multiple registered trials are underway as of 2024 and 2025.

Frequently asked questions

Is semaglutide the same thing as Ozempic or Wegovy?

Semaglutide is the active molecule. Ozempic and Wegovy are FDA-approved branded drugs that contain semaglutide as their active ingredient, manufactured by Novo Nordisk. They differ in approved dose ranges and indications: Ozempic is approved for type 2 diabetes and cardiovascular risk reduction, while Wegovy is approved for chronic weight management. Research-chemical semaglutide sold by peptide suppliers is not the same as these approved products and carries no FDA approval.

How does semaglutide differ from older GLP-1 receptor agonists like liraglutide?

The main practical difference is half-life. Liraglutide (Victoza, Saxenda) has a half-life of about 13 hours and requires daily injection. Semaglutide's albumin-binding fatty acid modification extends its half-life to roughly one week, enabling once-weekly subcutaneous dosing. In head-to-head trials, semaglutide also produced larger reductions in HbA1c and body weight than liraglutide at the doses studied. Semaglutide is also available as a once-daily oral tablet, which liraglutide is not.

What does the evidence say about weight regain after stopping semaglutide?

The STEP 4 trial, published in JAMA in 2021 with 803 participants, directly studied this question. Participants who lost weight on semaglutide for 20 weeks were then randomized to continue semaglutide or switch to placebo for another 48 weeks. Those who switched to placebo regained about two-thirds of their prior weight loss by the end of the study, while those who continued semaglutide kept losing weight. This suggests the weight-lowering effect depends on continued use, which is consistent with how the drug works mechanically rather than producing a permanent metabolic change.

Sources

  1. Marso et al., 2016, New England Journal of Medicine (SUSTAIN-6) Cardiovascular outcomes RCT, 3,297 participants
  2. Wilding et al., 2021, New England Journal of Medicine (STEP 1) Weight management RCT, 1,961 participants without diabetes
  3. Lincoff et al., 2023, New England Journal of Medicine (SELECT) Cardiovascular outcomes in obesity without diabetes
  4. Perkovic et al., 2024, New England Journal of Medicine (FLOW) Kidney outcomes RCT in type 2 diabetes

Educational and informational content only. This is not medical advice, diagnosis, or treatment. The compounds discussed are research compounds that are not approved for human use outside specific prescribed contexts. Always consult a qualified, licensed clinician before making any health decision.